## Joakim E Swedberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9213342/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An Ultrapotent and Selective Cyclic Peptide Inhibitor of Human β-Factor XIIa in a Cyclotide Scaffold. Journal of the American Chemical Society, 2021, 143, 18481-18489.	13.7	22
2	Binding Loop Substitutions in the Cyclic Peptide SFTI-1 Generate Potent and Selective Chymase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 816-826.	6.4	13
3	Innentitelbild: Application and Structural Analysis of Triazoleâ€Bridged Disulfide Mimetics in Cyclic Peptides (Angew. Chem. 28/2020). Angewandte Chemie, 2020, 132, 11258-11258.	2.0	0
4	Application and Structural Analysis of Triazoleâ€Bridged Disulfide Mimetics in Cyclic Peptides. Angewandte Chemie - International Edition, 2020, 59, 11273-11277.	13.8	27
5	Application and Structural Analysis of Triazoleâ€Bridged Disulfide Mimetics in Cyclic Peptides. Angewandte Chemie, 2020, 132, 11369-11373.	2.0	7
6	Iterative Optimization of the Cyclic Peptide SFTI-1 Yields Potent Inhibitors of Neutrophil Proteinase 3. ACS Medicinal Chemistry Letters, 2019, 10, 1234-1239.	2.8	12
7	Potent, multi-target serine protease inhibition achieved by a simplified β-sheet motif. PLoS ONE, 2019, 14, e0210842.	2.5	7
8	KLK4 Inhibition by Cyclic and Acyclic Peptides: Structural and Dynamical Insights into Standard-Mechanism Protease Inhibitors. Biochemistry, 2019, 58, 2524-2533.	2.5	13
9	Rapid and Scalable Plant-Based Production of a Potent Plasmin Inhibitor Peptide. Frontiers in Plant Science, 2019, 10, 602.	3.6	24
10	Amino Acid Scanning at P5′ within the Bowman–Birk Inhibitory Loop Reveals Specificity Trends for Diverse Serine Proteases. Journal of Medicinal Chemistry, 2019, 62, 3696-3706.	6.4	13
11	Characterising the Subsite Specificity of Urokinaseâ€Type Plasminogen Activator and Tissueâ€Type Plasminogen Activator using a Sequenceâ€Defined Peptide Aldehyde Library. ChemBioChem, 2019, 20, 46-50.	2.6	5
12	Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma. Journal of Medicinal Chemistry, 2019, 62, 552-560.	6.4	27
13	Conformational Flexibility Is a Determinant of Permeability for Cyclosporin. Journal of Physical Chemistry B, 2018, 122, 2261-2276.	2.6	104
14	Calcium-Mediated Allostery of the EGF Fold. ACS Chemical Biology, 2018, 13, 1659-1667.	3.4	10
15	Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II. ACS Medicinal Chemistry Letters, 2018, 9, 1258-1262.	2.8	25
16	Engineering potent mesotrypsin inhibitors based on the plant-derived cyclic peptide, sunflower trypsin inhibitor-1. European Journal of Medicinal Chemistry, 2018, 155, 695-704.	5.5	20
17	Design of Potent and Selective Cathepsin G Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold. Journal of Medicinal Chemistry, 2017, 60, 658-667.	6.4	48
18	Structural and functional characterization of chimeric cyclotides from the Möbius and trypsin inhibitor subfamilies. Biopolymers, 2017, 108, e22927.	2.4	11

JOAKIM E SWEDBERG

#	Article	IF	CITATIONS
19	Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum. Journal of Investigative Dermatology, 2017, 137, 430-439.	0.7	50
20	Effects of linker sequence modifications on the structure, stability, and biological activity of a cyclic αâ€conotoxin. Biopolymers, 2016, 106, 864-875.	2.4	10
21	Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro. Journal of Biological Chemistry, 2016, 291, 15778-15787.	3.4	10
22	Substrate-Guided Design of Selective FXIIa Inhibitors Based on the Plant-Derived <i>Momordica cochinchinensis</i> Trypsin Inhibitor-II (MCoTI-II) Scaffold. Journal of Medicinal Chemistry, 2016, 59, 7287-7292.	6.4	34
23	Diverse cyclic seed peptides in the Mexican zinnia ( Zinnia haageana ). Biopolymers, 2016, 106, 806-817.	2.4	13
24	Direct and indirect mechanisms of KLK4 inhibition revealed by structure and dynamics. Scientific Reports, 2016, 6, 35385.	3.3	28
25	Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors. Biological Chemistry, 2016, 397, 1237-1249.	2.5	28
26	Engineered protease inhibitors based on sunflower trypsin inhibitor-1 (SFTI-1) provide insights into the role of sequence and conformation in Laskowski mechanism inhibition. Biochemical Journal, 2015, 469, 243-253.	3.7	57
27	Effects of Cyclization on Peptide Backbone Dynamics. Journal of Physical Chemistry B, 2015, 119, 15821-15830.	2.6	36
28	Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability. European Journal of Medicinal Chemistry, 2015, 97, 202-213.	5.5	76
29	Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library. Journal of Medicinal Chemistry, 2015, 58, 8257-8268.	6.4	51
30	Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists. European Journal of Medicinal Chemistry, 2015, 103, 175-184.	5.5	20
31	The Evolution of <i>Momordica</i> Cyclic Peptides. Molecular Biology and Evolution, 2015, 32, 392-405.	8.9	26
32	Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 InÂVitro. Chemistry and Biology, 2014, 21, 284-294.	6.0	63
33	Translational Diffusion of Cyclic Peptides Measured Using Pulsed-Field Gradient NMR. Journal of Physical Chemistry B, 2014, 118, 11129-11136.	2.6	35
34	Disulfide-rich macrocyclic peptides as templates in drug design. European Journal of Medicinal Chemistry, 2014, 77, 248-257.	5.5	117
35	Mechanismâ€based selection of a potent kallikreinâ€related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTIâ€1. Biopolymers, 2013, 100, 510-518.	2.4	38
36	Paclitaxel Resistance and Multicellular Spheroid Formation Are Induced by Kallikrein-Related Peptidase 4 in Serous Ovarian Cancer Cells in an Ascites Mimicking Microenvironment. PLoS ONE, 2013, 8, e57056.	2.5	47

JOAKIM E SWEDBERG

#	Article	IF	CITATIONS
37	Recent Progress Towards Pharmaceutical Applications of Disulfide-Rich Cyclic Peptides. Current Protein and Peptide Science, 2013, 14, 532-552.	1.4	25
38	Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14. Biological Chemistry, 2012, 393, 331-341.	2.5	26
39	6 Natural, Engineered and Synthetic Inhibitors of Kallikrein-related Peptidases. , 2012, , 141-160.		1
40	Cyclotides as a basis for drug design. Expert Opinion on Drug Discovery, 2012, 7, 179-194.	5.0	102
41	Selective Cleavage of Human Sex Hormone-Binding Globulin by Kallikrein-Related Peptidases and Effects on Androgen Action in LNCaP Prostate Cancer Cells. Endocrinology, 2012, 153, 3179-3189.	2.8	11
42	Natural and Engineered Plasmin Inhibitors: Applications and Design Strategies. ChemBioChem, 2012, 13, 336-348.	2.6	19
43	Plasmin Substrate Binding Site Cooperativity Guides the Design of Potent Peptide Aldehyde Inhibitors. Biochemistry, 2011, 50, 8454-8462.	2.5	37
44	Mastering the Canonical Loop of Serine Protease Inhibitors: Enhancing Potency by Optimising the Internal Hydrogen Bond Network. PLoS ONE, 2011, 6, e19302.	2.5	61
45	Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia. Biological Chemistry, 2010, 391, 357-74.	2.5	35
46	Substrate-Guided Design of a Potent and Selective Kallikrein-Related Peptidase Inhibitor for Kallikrein 4. Chemistry and Biology, 2009, 16, 633-643.	6.0	109